In a new series on the Help4HD podcast, host Lauren Holder will meet with members of the HDBuzz editorial staff to discuss hot topics in HD science. The first of these roundtable discussions went live last week. Esteemed clinician Dr. Ed Wild and expert HD scientist Dr. Rachel Harding gave a recap of research highlights from HDSA’s 37th annual convention, discussed highs and lows of the last three years in the HD research landscape, and looked forward to exciting endeavors on the horizon. To listen to the full episode, click here.
An Expert’s Opinion: Where does tominersen go from here?
The highly anticipated GENERATION-HD1 study of tominersen for HD halted in March of 2021. Since then, data analysis has shed light on what may have gone wrong, and given Roche reason to believe that the drug may be effective in a more specific target population: younger individuals with lower disease burden. With these findings in mind, HD specialist, Dr. Neil Aronin, weighs in on the challenges that may have led to the halting of GENERATION-HD1, and explores the advantages of continuing to develop tominersen for treatment of HD. To read the full article, published in the Journal of Huntington’s Disease, click here.
Beat the heat: Participate in HD research from home!
Researchers all over the world are seeking participants from the HD community to participate in survey-based studies on HD. Whether you have HD, are a care partner to someone with HD, a member of an HD family, or at risk for the disease, there is a study for you! Click here to see what survey studies are available and learn more about how you can get involved.
